Literature DB >> 15210689

Constitutive endocytic cycle of the CB1 cannabinoid receptor.

Christophe Leterrier1, Damien Bonnard, Damien Carrel, Jean Rossier, Zsolt Lenkei.   

Abstract

The CB1 cannabinoid receptor (CB1R) displays a significant level of ligand-independent (i.e. constitutive) activity, either when heterologously expressed in nonneuronal cells or in neurons where CB1Rs are endogenous. The present study investigates the consequences of constitutive activity on the intracellular trafficking of CB1R. When transfected in HEK-293 cells, CB1R is present at the plasma membrane, but a substantial proportion ( approximately 85%) of receptors is localized in intracellular vesicles. Detailed analysis of CB1-EGFP expressed in HEK-293 cells shows that the intracellular CB1R population is mostly of endocytic origin and that treatment with inverse agonist AM281 traps CB1R at the plasma membrane through a monensin-sensitive recycling pathway. Co-transfection with dominant positive or dominant negative mutants of the small GTPases Rab5 and Rab4, but not Rab11, profoundly modifies the steady-state and ligand-induced intracellular distribution of CB1R, indicating that constitutive endocytosis is Rab5-dependent, whereas constitutive recycling is mediated by Rab4. In conclusion, our results indicate that, due to its natural constitutive activity, CB1R permanently and constitutively cycles between plasma membrane and endosomes, leading to a predominantly intracellular localization at steady state.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210689     DOI: 10.1074/jbc.M403990200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  91 in total

1.  Endocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.

Authors:  Janis Noonan; Riffat Tanveer; Allan Klompas; Aoife Gowran; Joanne McKiernan; Veronica A Campbell
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization.

Authors:  Aaron M D'Antona; Kwang H Ahn; Debra A Kendall
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

Review 3.  Exocytosis in astrocytes: transmitter release and membrane signal regulation.

Authors:  Alenka Guček; Nina Vardjan; Robert Zorec
Journal:  Neurochem Res       Date:  2012-04-21       Impact factor: 3.996

Review 4.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  Visualizing odorant receptor trafficking in living cells down to the single-molecule level.

Authors:  V Jacquier; M Prummer; J-M Segura; H Pick; H Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-15       Impact factor: 11.205

Review 7.  Regulation of G protein-coupled receptor export trafficking.

Authors:  Chunmin Dong; Catalin M Filipeanu; Matthew T Duvernay; Guangyu Wu
Journal:  Biochim Biophys Acta       Date:  2006-09-23

8.  The G protein Gi1 exhibits basal coupling but not preassembly with G protein-coupled receptors.

Authors:  Alexey Bondar; Josef Lazar
Journal:  J Biol Chem       Date:  2017-04-24       Impact factor: 5.157

9.  Ligand-induced regulation and localization of cannabinoid CB1 and dopamine D2L receptor heterodimers.

Authors:  Julie A Przybyla; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-12-16       Impact factor: 4.030

Review 10.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.